258 related articles for article (PubMed ID: 12663439)
1. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.
Grundler R; Thiede C; Miething C; Steudel C; Peschel C; Duyster J
Blood; 2003 Jul; 102(2):646-51. PubMed ID: 12663439
[TBL] [Abstract][Full Text] [Related]
2. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
Bagrintseva K; Schwab R; Kohl TM; Schnittger S; Eichenlaub S; Ellwart JW; Hiddemann W; Spiekermann K
Blood; 2004 Mar; 103(6):2266-75. PubMed ID: 14604974
[TBL] [Abstract][Full Text] [Related]
3. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.
Spiekermann K; Dirschinger RJ; Schwab R; Bagrintseva K; Faber F; Buske C; Schnittger S; Kelly LM; Gilliland DG; Hiddemann W
Blood; 2003 Feb; 101(4):1494-504. PubMed ID: 12406902
[TBL] [Abstract][Full Text] [Related]
4. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
O'Farrell AM; Abrams TJ; Yuen HA; Ngai TJ; Louie SG; Yee KW; Wong LM; Hong W; Lee LB; Town A; Smolich BD; Manning WC; Murray LJ; Heinrich MC; Cherrington JM
Blood; 2003 May; 101(9):3597-605. PubMed ID: 12531805
[TBL] [Abstract][Full Text] [Related]
5. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.
Choudhary C; Schwäble J; Brandts C; Tickenbrock L; Sargin B; Kindler T; Fischer T; Berdel WE; Müller-Tidow C; Serve H
Blood; 2005 Jul; 106(1):265-73. PubMed ID: 15769897
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
Kindler T; Breitenbuecher F; Kasper S; Estey E; Giles F; Feldman E; Ehninger G; Schiller G; Klimek V; Nimer SD; Gratwohl A; Choudhary CR; Mueller-Tidow C; Serve H; Gschaidmeier H; Cohen PS; Huber C; Fischer T
Blood; 2005 Jan; 105(1):335-40. PubMed ID: 15345593
[TBL] [Abstract][Full Text] [Related]
7. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).
Murata K; Kumagai H; Kawashima T; Tamitsu K; Irie M; Nakajima H; Suzu S; Shibuya M; Kamihira S; Nosaka T; Asano S; Kitamura T
J Biol Chem; 2003 Aug; 278(35):32892-8. PubMed ID: 12815052
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor.
Tse KF; Novelli E; Civin CI; Bohmer FD; Small D
Leukemia; 2001 Jul; 15(7):1001-10. PubMed ID: 11455967
[TBL] [Abstract][Full Text] [Related]
9. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.
Mizuki M; Fenski R; Halfter H; Matsumura I; Schmidt R; Müller C; Grüning W; Kratz-Albers K; Serve S; Steur C; Büchner T; Kienast J; Kanakura Y; Berdel WE; Serve H
Blood; 2000 Dec; 96(12):3907-14. PubMed ID: 11090077
[TBL] [Abstract][Full Text] [Related]
10. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
[TBL] [Abstract][Full Text] [Related]
11. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.
Yee KW; O'Farrell AM; Smolich BD; Cherrington JM; McMahon G; Wait CL; McGreevey LS; Griffith DJ; Heinrich MC
Blood; 2002 Oct; 100(8):2941-9. PubMed ID: 12351406
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
Tse KF; Allebach J; Levis M; Smith BD; Bohmer FD; Small D
Leukemia; 2002 Oct; 16(10):2027-36. PubMed ID: 12357354
[TBL] [Abstract][Full Text] [Related]
13. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).
Bagrintseva K; Geisenhof S; Kern R; Eichenlaub S; Reindl C; Ellwart JW; Hiddemann W; Spiekermann K
Blood; 2005 May; 105(9):3679-85. PubMed ID: 15626738
[TBL] [Abstract][Full Text] [Related]
14. Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.
Jiang J; Paez JG; Lee JC; Bo R; Stone RM; DeAngelo DJ; Galinsky I; Wolpin BM; Jonasova A; Herman P; Fox EA; Boggon TJ; Eck MJ; Weisberg E; Griffin JD; Gilliland DG; Meyerson M; Sellers WR
Blood; 2004 Sep; 104(6):1855-8. PubMed ID: 15178581
[TBL] [Abstract][Full Text] [Related]
15. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112.
Yang X; Liu L; Sternberg D; Tang L; Galinsky I; DeAngelo D; Stone R
Cancer Res; 2005 Aug; 65(16):7338-47. PubMed ID: 16103085
[TBL] [Abstract][Full Text] [Related]
16. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T
Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
[TBL] [Abstract][Full Text] [Related]
17. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3.
Teller S; Krämer D; Böhmer SA; Tse KF; Small D; Mahboobi S; Wallrapp C; Beckers T; Kratz-Albers K; Schwäble J; Serve H; Böhmer FD
Leukemia; 2002 Aug; 16(8):1528-34. PubMed ID: 12145694
[TBL] [Abstract][Full Text] [Related]
18. A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia.
Spiekermann K; Bagrintseva K; Schoch C; Haferlach T; Hiddemann W; Schnittger S
Blood; 2002 Nov; 100(9):3423-5. PubMed ID: 12384447
[TBL] [Abstract][Full Text] [Related]
19. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.
Yamamoto Y; Kiyoi H; Nakano Y; Suzuki R; Kodera Y; Miyawaki S; Asou N; Kuriyama K; Yagasaki F; Shimazaki C; Akiyama H; Saito K; Nishimura M; Motoji T; Shinagawa K; Takeshita A; Saito H; Ueda R; Ohno R; Naoe T
Blood; 2001 Apr; 97(8):2434-9. PubMed ID: 11290608
[TBL] [Abstract][Full Text] [Related]
20. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines.
Hayakawa F; Towatari M; Kiyoi H; Tanimoto M; Kitamura T; Saito H; Naoe T
Oncogene; 2000 Feb; 19(5):624-31. PubMed ID: 10698507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]